Lyell Immunopharma, Inc.
LYEL
$12.89
$0.191.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.00K | 36.00K | 41.00K | 60.00K | 65.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.00K | 36.00K | 41.00K | 60.00K | 65.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 31.00K | 36.00K | 41.00K | 60.00K | 65.00K |
| SG&A Expenses | 40.64M | 45.14M | 49.04M | 50.12M | 52.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -6.16M | -5.67M | -5.78M | -4.92M | -4.55M |
| Total Operating Expenses | 186.32M | 198.14M | 198.41M | 211.68M | 219.92M |
| Operating Income | -186.29M | -198.10M | -198.37M | -211.62M | -219.85M |
| Income Before Tax | -246.41M | -274.45M | -325.66M | -331.40M | -334.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -246.41 | -274.45 | -325.66 | -331.40 | -334.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -246.41M | -274.45M | -325.66M | -331.40M | -334.52M |
| EBIT | -186.29M | -198.10M | -198.37M | -211.62M | -219.85M |
| EBITDA | -175.86M | -186.57M | -184.20M | -195.34M | -201.80M |
| EPS Basic | -12.98 | -15.41 | -22.26 | -23.61 | -24.32 |
| Normalized Basic EPS | -5.98 | -7.45 | -7.64 | -8.49 | -9.09 |
| EPS Diluted | -12.98 | -15.41 | -22.26 | -23.61 | -24.32 |
| Normalized Diluted EPS | -5.98 | -7.45 | -7.64 | -8.49 | -9.09 |
| Average Basic Shares Outstanding | 75.45M | 68.33M | 61.81M | 56.36M | 54.34M |
| Average Diluted Shares Outstanding | 75.45M | 68.33M | 61.81M | 56.36M | 54.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |